Back to Newsroom

Sucampo to Present Results From Four Phase 3 Studies of AMITIZA(R) (lubiprostone) for Opioid-Induced Constipation at PAINWeek 2013

BETHESDA, Md., Sept. 4, 2013 — Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) (“Sucampo”) will be presenting data from four separate phase 3 studies evaluating the overall efficacy of AMITIZA (lubiprostone) as a treatment for adults with chronic, non-cancer pain suffering from opioid-induced constipation (OIC).